Enterprise Value

-84.18M

Cash

228.2M

Avg Qtr Burn

-29.75M

Short % of Float

4.52%

Insider Ownership

2.20%

Institutional Own.

-

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ANX005 (IV) Details
Guillian-Barre syndrome, Autoimmune disease

Phase 2/3

Data readout

ANX005 (IV) Details
Huntington's disease, Brain disease

Phase 2/3

Initiation

ANX005 (IV) Details
Warm autoimmune hemolytic anemia, Autoimmune disease

Phase 2

Update

ANX007 (IVT) Details
Geographic atrophy

Phase 2

Update

ANX005 (IV) Details
Amyotrophic lateral sclerosis, Neurodegenerative disease

Phase 2a

Data readout

ANX009 Details
Lupus nephritis

Phase 1b

Data readout

ANX105 Details
Autoimmune disease, Neurodegenerative disease

Phase 1

Data readout

ANX1502 Details
Autoimmune disease

Phase 1a

Data readout